ENTITY

MetaVia (MTVA US)

24
Analysis
Health Care • United States
MetaVia Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing dual oxyntomodulin (OXM) analog agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). MetaVia serves customers worldwide.
more
Company Event • 07 Nov 2026 05:00 • Upcoming
Add To Calendar

Q3 2026

Company Event • 06 Aug 2026 21:30 • Upcoming
Add To Calendar

Q2 2026

Company Event • 06 Aug 2026 20:00 • Upcoming
Add To Calendar

Investor presentation

Company Event • 24 Jun 2026 22:30 • Latest

Life Sciences Virtual Investor Forum

Company Event • 12 Jun 2026 03:40

Emerging Growth Conference 93

x